Actively Recruiting
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Led by Chong Kun Dang Pharmaceutical · Updated on 2025-12-11
324
Participants Needed
1
Research Sites
115 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A(Sacubitril∙Valsartan)
CONDITIONS
Official Title
Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants who are 19 years old or older.
- Participants who have voluntarily decided to participate in this clinical trial and signed informed consent form.
You will not qualify if you...
- History of secondary or suspected secondary hypertension.
- Presence of orthostatic hypotension.
- Need for combination antihypertensive drugs other than the study drugs during the trial.
- Type 1 diabetes or poorly controlled diabetes.
- Participation in another clinical trial with investigational drugs within 4 weeks before screening.
- History of drug or alcohol abuse within 24 weeks prior to screening.
- Pregnant or breastfeeding women, or those not agreeing to use contraception during and for two weeks after the study.
- Inability to participate as determined by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Wonju Severance Christian Hospital
Wŏnju, South Korea
Actively Recruiting
Research Team
K
Keehyun Ham, Project Leader
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here